AbbVie vs Merck & Co

AbbVie (ABBV), health care, and Merck & Co (MRK), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

AbbVie is worth $518.9B on the stock market and Merck & Co $355.1B: AbbVie is valued at 46% more. AbbVie trades at 50.5 times earnings and Merck & Co at 145. Over the past year AbbVie's share price has moved +25.9% and Merck & Co's +49.8%.

Key facts

AbbVie market value
$518.9B
Merck & Co market value
$355.1B
AbbVie P/E
50.5
Merck & Co P/E
145
AbbVie revenue
$61.2BFY to 2025-12-31
Merck & Co revenue
$65BFY to 2025-12-31
Superinvestors holding both
10

Market values as of .

AbbVie vs Merck & Co: every measure side by side
Measure AbbVie Merck & Co
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$518.9Bhigher$355.1Blower
Revenue$61.2Blower$65Bhigher
Earnings$4.2Blower$18.3Bhigher
Employees57,000lower73,000higher
Total assets$134Blower$136.9Bhigher
Valuation
P/E50.5lower145higher
P/S8.5higher5.5lower
P/B—7.9
Dividend yield2.35%higher2.33%lower
Profitability
Operating margin24.6%—
Balance sheet
Net assets-$3.3Blower$52.6Bhigher
Total liabilities$137.2Bhigher$84.2Blower
Total debt$67.5Bhigher$49.3Blower
Cash on hand$5.2Blower$14.6Bhigher
Price change
Today-0.33%lower-0.29%higher
1 year+25.9%lower+49.8%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Percentages are each holding's share of that investor's reported portfolio (under "Both": AbbVie / Merck & Co). Who owns ABBV · Who owns MRK

Further comparisons

Learn

Questions and answers

Which is bigger, AbbVie or Merck & Co?

By market value, AbbVie is the larger: $518.9B against $355.1B for Merck & Co. By revenue in its latest fiscal year, Merck & Co is the larger: $65B against $61.2B for AbbVie.

Which has the higher P/E ratio?

Merck & Co: 145, against 50.5 for AbbVie. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has the higher dividend yield?

AbbVie: 2.35%, against 2.33% for Merck & Co. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which has more debt?

AbbVie: $67.5B, against $49.3B for Merck & Co. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

Which superinvestors own both AbbVie and Merck & Co?

In their latest 13F filings, Ken Fisher, Ken Griffin, David Shaw (founder), Cliff Asness, Mairs & Power team, Murray Stahl, Thomas Russo, Howard Gleicher, Rajiv Jain and Bill Nygren hold both.

Cite this page

Funkfolio, “AbbVie vs Merck & Co”, data as of 17 November 2026. https://funkfolio.com/compare/abbv-vs-mrk

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.